Patents by Inventor Mark F. Stinski

Mark F. Stinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Truncated CMV promoters and vectors containing same
    Patent number: 7407801
    Abstract: The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by such vectors. The nucleic acid molecules, vectors and transformed host cells of the present invention are useful for treating a variety of genetic, metabolic and acquired diseases, including inter alia cystic fibrosis (CF) airway disease.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: August 5, 2008
    Assignees: University of Iowa Research Foundation, National Institutes of Health (NIH)
    Inventors: Lynda S. Ostedgaard, Michael J. Welsh, Mark F. Stinski, John A. Chiorini
  • Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter regulatory DNA sequence
    Patent number: 5385839
    Abstract: The cloning of a eucaryotic promoter-regulatory region that functions preferentially in human cells is disclosed. The invention is exemplified by the cloning of a section of the human cytomegalovirus genome comprising a DNA sequence with regulatory and promoter signals and an initiation site for RNA synthesis. The fragment, termed the human cytomegalovirus (HCMV) promoter-regulatory sequence, was obtained from purified HCMV DNA.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: January 31, 1995
    Assignee: University of Iowa Research Foundation
    Inventor: Mark F. Stinski
  • Early envelope glycoprotein of human cytomegalovirus (HMCV) and monoclonal antibodies to the glycoproteins
    Patent number: 5180813
    Abstract: The present invention provides an envelope glycoprotein which is encoded by an early structural gene of human cytomegalovirus, and polyclonal and monoclonal antibodies to the early envelope glycoprotein.
    Type: Grant
    Filed: March 24, 1989
    Date of Patent: January 19, 1993
    Assignee: University of Iowa Research Foundation
    Inventor: Mark F. Stinski
  • Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
    Patent number: 5168062
    Abstract: The cloning of a eucaryotic promoter-regulatory region that functions preferentially in human cells is disclosed. The invention is exemplified by the cloning of a section of the human cytomegalovirus genome comprising a DNA sequence with regulatory and promoter signals and an initiation site for RNA synthesis. The fragment, termed the human cytomegalovirus (HCMV) promoter-regulatory sequence, was obtained from purified HCMV DNA.
    Type: Grant
    Filed: September 10, 1990
    Date of Patent: December 1, 1992
    Assignee: University of Iowa Research Foundation
    Inventor: Mark F. Stinski
  • Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
    Patent number: 5124440
    Abstract: Glycopeptides of the gcI (gB) complex of human cytomegalovirus are disclosed. They possess unique B cell and T cell epitopes not present in other gcI glycopeptides. Glycopeptide fragments which comprise minimal antigenic determinants of the gcI complex are also disclosed, as are recombinant expression vectors, vaccines, and diagnostic methods.
    Type: Grant
    Filed: March 24, 1989
    Date of Patent: June 23, 1992
    Assignees: The Childrens Hospital, Inc., University of Iowa Research Foundation
    Inventors: Richard C. Gehrz, Mark F. Stinski, Bruce I. Kari, Yung-Nan Liu